Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, June 13, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, June 12, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Michael Ulz Maintained (AKRO) at Buy with Increased Target to $70 on, Jun 12th, 2023
Michael Ulz of Morgan Stanley, Maintained "Akero Therapeutics, Inc." (AKRO) at Buy with Increased Target from $65 to $70 on, Jun 12th, 2023.
Michael has made no other calls on AKRO in the last 4 months.
There are 2 other peers that have a rating on AKRO. Out of the 2 peers that are also analyzing AKRO, 0 agree with Michael's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Michael
- Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $64 on, Wednesday, June 7th, 2023
- Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $59 on, Wednesday, May 17th, 2023
